ReviewFrontiers in oncology2021
Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Comparative Analysis of Lesion Detection and Uptake Characteristics ofJournal of gastrointestinal cancer · 2026Article
- Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- 99mTc-FAPI-YQ3 SPECT/CT for characterizing FAPI uptake phenotypes and metabolic-stromal heterogeneity in advanced differentiated thyroid carcinoma: a prospective single-center imaging-radiomics study.Frontiers in immunology · 2026Observational
- Cancer-Associated Fibroblasts in Gastrointestinal Cancer Metastasis: Mechanisms and Emerging Therapeutic Strategies.Drug design, development and therapy · 2026Review
- Cancer-associated fibroblasts at the crossroads of tumor progression and therapy resistance: from heterogeneity to precision reprogramming.Journal of the Egyptian National Cancer Institute · 2025Review
- Preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2025Article
- Macrocyclic Phage Display for Identification of Selective Protease Substrates.Journal of the American Chemical Society · 2025Article
- Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Evaluation ofClinical and translational radiation oncology · 2024Article
- FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review.Journal of biomedical physics & engineering · 2024Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- The role of [European journal of nuclear medicine and molecular imaging · 2024Article
- Dual-tracer PET/CT protocol with [Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- The comparative utility of FAPI-based PET radiotracers over [American journal of nuclear medicine and molecular imaging · 2024Review
- Tumor Progression from a Fibroblast Activation Protein Perspective: Novel Diagnostic and Therapeutic Scenarios for Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- The Potential Role of the T2 Ribonucleases in TME-Based Cancer Therapy.Biomedicines · 2023Review
- A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.Radiology. Imaging cancer · 2023Review
- The roles of proteases in prostate cancer.IUBMB life · 2023Review
- Special Issue "In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research".Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), is a novel target for molecular imaging of various tumors. Recently, the development of several small-molecule FAP inhibitors for radiolabeling with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.